Semaglutide: what it actually does inside your body
The science behind the most-discussed drug in a generation — and what it means beyond weight loss.
Semaglutide: what it actually does inside your body
The science behind the most-discussed drug in a generation — and what it means beyond weight loss.
pru
THE PRU BRIEF
SCIENCE & WELLBEING
ISSUE NO. 08
Semaglutide: what it actually does inside your body
The science behind the most-discussed drug in a generation — and what it means beyond weight loss.
Dear Pru Community,
By now you've almost certainly heard of semaglutide. It's the active ingredient in Ozempic and Wegovy — two brand names that have dominated health conversations, magazine covers, and social media feeds for the past two years. More than 1 in 8 Americans is now taking a GLP-1 medication, and semaglutide is the compound most of them are on.
But the popular conversation around semaglutide has been almost entirely about what it does — weight loss — and almost nothing about how it does it. That's the gap we want to close this issue. Understanding the mechanism matters, because it changes how you think about who this is for, what its limits are, and where the science is heading next.
What semaglutide actually is
Semaglutide is a synthetic analogue of GLP-1 — glucagon-like peptide-1 — a hormone your gut produces naturally after you eat. In your body, GLP-1 has a very short half-life of about two minutes before enzymes break it down. Semaglutide was engineered to solve that problem: with a half-life of approximately seven days, a single weekly injection maintains steady, stable levels where your own GLP-1 would have flickered out almost instantly.
It achieves this longevity primarily through two structural modifications. First, a single amino acid substitution at position 8 makes it resistant to the enzyme (DPP-4) that normally degrades GLP-1. Second, a fatty acid chain is attached that binds tightly to albumin — a protein abundant in your bloodstream — which further slows clearance and extends its action. The result is a molecule that behaves like your body's own satiety hormone, but at far higher concentrations and for far longer.
THREE SYSTEMS, ONE SIGNAL
The mechanism: it's not just appetite suppression
Most coverage of semaglutide frames it as a drug that makes you less hungry. That's true, but it's an incomplete picture. GLP-1 receptors are distributed throughout the body — in the brain, the gut, the pancreas, the heart, and even the kidneys — and semaglutide activates all of them simultaneously. The result is a multi-system effect that researchers are still mapping.
In the brain, semaglutide acts on the hypothalamus and brainstem to reduce the drive to eat — not just by dampening hunger signals, but by modulating the reward circuitry that makes food feel urgent in the first place. This is why patients often report that food simply feels less compelling, not that they're white-knuckling through cravings.
In the gut, it slows gastric emptying — the rate at which food moves from your stomach into the small intestine. Food stays in your stomach longer, fullness signals persist, and caloric intake drops without requiring conscious restraint. In the pancreas, it stimulates insulin release in a glucose-dependent way — meaning it only triggers insulin when blood sugar is actually elevated, which dramatically reduces the risk of hypoglycemia compared to older diabetes medications.
What the clinical evidence actually shows
The STEP trial program — a series of large, rigorous randomized controlled trials published between 2021 and 2023 — established the benchmark figures that get quoted everywhere. In STEP 1, participants on semaglutide 2.4mg weekly lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group. Roughly one-third of participants lost more than 20%.
But the numbers that have generated the most scientific interest are the cardiovascular ones. The SELECT trial, published in The New England Journal of Medicine in 2023, enrolled over 17,000 overweight or obese adults without diabetes who had established cardiovascular disease. Semaglutide reduced major cardiovascular events — heart attack, stroke, and cardiovascular death — by 20% over a median follow-up of 34 months. This was not expected. The trial was designed to check for harm, not to demonstrate benefit of that magnitude.
Researchers are now investigating whether the cardiovascular benefit is driven by weight loss alone, or whether semaglutide has direct anti-inflammatory effects on blood vessel walls independent of the weight change. Early mechanistic data suggests the latter is at least partly true — GLP-1 receptors are present in the heart and vascular tissue, and animal studies have shown direct cardioprotective effects. Human data to confirm this is still emerging.
14.9%
average body weight lost in STEP 1 trial (68 weeks)
20%
reduction in major cardiovascular events (SELECT trial)
~7 days
half-life, enabling once-weekly dosing
Side effects: what's common, what's rare, and what's still being studied
The most frequently reported side effects — nausea, vomiting, diarrhea, and constipation — are a direct consequence of the gut mechanism. Slowing gastric emptying can cause discomfort, particularly in the early weeks of treatment and when doses are increased. These effects typically diminish as the body adjusts, and a gradual dose escalation protocol (which is standard practice) significantly reduces their severity for most people.
Muscle mass loss is a more meaningful concern. In the STEP trials, approximately one-third of total weight lost came from lean mass rather than fat. This is not unique to semaglutide — it's a feature of almost all significant weight loss — but it underscores why resistance training and adequate protein intake aren't optional for people on this medication. Without deliberate effort, you may lose weight in a composition that undermines long-term metabolic health.
The rare but serious risks are worth naming clearly. Pancreatitis has been reported, though causality versus association remains debated in the literature. Animal studies showed thyroid C-cell tumors at high doses, which is why semaglutide carries a boxed warning and is contraindicated in people with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2. These tumors have not been observed in human trials, but the precaution stands.
The research frontier: beyond weight and metabolic health
What's generating real scientific excitement — and considerable caution — is early evidence that GLP-1 receptor agonists may have broader biological effects than originally understood. Observational data has suggested lower rates of Alzheimer's disease among diabetic patients taking GLP-1 drugs. Neuroinflammation is now considered a driver of neurodegenerative disease, and GLP-1 receptors in the brain appear to have anti-inflammatory effects on microglial cells. Several clinical trials are now underway specifically targeting early Alzheimer's with semaglutide and similar compounds.
Researchers are also investigating potential benefits in liver disease (NASH/MASH), sleep apnea — which showed meaningful improvement in a 2024 trial — kidney disease, and addiction. The addiction research is particularly striking: GLP-1 receptor activation appears to dampen the dopamine reward response not just to food, but to alcohol and possibly other addictive stimuli. Several trials on alcohol use disorder are currently recruiting. None of this is established clinical practice yet, but it reframes semaglutide from a weight loss drug into something that might be better described as a metabolic and inflammatory modulator with a very broad biological footprint.
WORTH READING
Lincoff, A.M. et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 389, pp. 2221–2232. (The SELECT trial.)
Wilding, J.P.H. et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, pp. 989–1002. (The STEP 1 trial.)
Semaglutide at Pru: what safe access actually looks like
Semaglutide is one of the most rigorously studied compounds we offer — and that evidence base is precisely why we take how it's prescribed seriously. Every Pru semaglutide protocol begins with a thorough intake, baseline labs, and a one-on-one consultation with a licensed U.S. clinician. Your provider reviews your health history, current medications, and goals before any prescription is written. Nothing is automated. Nothing is rubber-stamped.
When your medication ships, it comes from licensed, accredited American compounding pharmacies operating under strict federal and state standards — not from overseas suppliers, not from unregulated gray-market channels. Every batch is tested for purity, potency, and sterility. You receive what the label says, at the dose your clinician prescribed.
Ongoing oversight is part of how Pru works. Dose adjustments, check-ins on side effects, and reassessment of your protocol over time are not optional add-ons — they are how responsible semaglutide therapy is supposed to be practiced. The STEP 4 trial showed clearly that weight returns when medication stops without lifestyle foundations in place. That's why your protocol includes guidance on protein targets and resistance training, not just a prescription. We are here for your long-term health, not a short-term number on a scale.
This newsletter is for educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. Semaglutide requires a prescription and must be evaluated for individual suitability by a licensed clinician. Always consult your provider before starting, adjusting, or stopping any medication.